COMPARISON
Cetrorelix vs Ganirelix
5 attributes held for at least one of the two. 4 differ. Each value carries the register it came from and the date that register was read.
Answer
Cetrorelix is authorised or registered in 10 and Ganirelix in 10 of the 10 registers read. Cetrorelix: No trial states a phase. Ganirelix: highest phase Phase 4 (after approval). 18 registered trials include both.
States no view on which is preferable, safer or more effective. Not medical advice.
| Cetrorelix | Ganirelix | |
|---|---|---|
| Registered trials differs | 140 clinicaltrials.gov · 2026-10-03 | 108 clinicaltrials.gov · 2026-10-03 |
| FDA label differs | FDA-approved: cetrorelix acetate openfda · 2026-10-03T17:23:44.062Z | FDA-approved: Ganirelix Acetate openfda · 2026-10-03T17:23:44.062Z |
| EU authorisation | Authorised ema · 2026-10-03 | Authorised ema · 2026-10-03 |
| EU authorised on differs | 1999-04-12 ema · 2026-10-03 | 2000-05-16 ema · 2026-10-03 |
| ATC code differs | H01CC02 ema · 2026-10-03 | H01CC01 ema · 2026-10-03 |
SIDE EFFECTS
Most common side effects, each beside its own placebo
| Side effect | Cetrorelix | placebo | Ganirelix | placebo |
|---|---|---|---|---|
| Nasopharyngitis | 8.9% | 8.7% | - | - |
| Injection site pain | 8.5% | 3.7% | - | - |
| Headache | 7.3% | 7.3% | - | - |
| Upper respiratory infection | 6.9% | 6.0% | - | - |
| Back pain | 6.2% | 6.4% | - | - |
| Diarrhea | 6.0% | 2.8% | - | - |
| Musculoskeletal pain | 6.0% | 2.8% | - | - |
| PSA increased | 5.6% | 2.3% | - | - |
| Hypertension | 4.7% | 5.5% | - | - |
| Arthralgia | 4.2% | 4.6% | - | - |
Trial register Cetrorelix: 2 placebo-controlled trials; Ganirelix: 0. Each peptide is compared with placebo in its own trials, not with the other: a dash means the event is not in that peptide's top list. Cetrorelix side effects · Ganirelix side effects
LEGAL STATUS
Approval in each country read
| Country | Cetrorelix | Ganirelix | Register |
|---|---|---|---|
| United States | FDA-approved | FDA-approved | Regulator FDA |
| European Union | Authorised | Authorised | Regulator EMA |
| United Kingdom | Authorised | Authorised | Regulator MHRA |
| Canada | Authorised | Authorised | Regulator Health Canada |
| Australia | Registered | Registered | Regulator TGA |
| Switzerland | Authorised | Authorised | Regulator Swissmedic |
| Brazil | Registado | Registado | Regulator ANVISA |
| Serbia | Authorised | Authorised | Regulator ALIMS |
| Singapore | Registered | Registered | Regulator HSA |
| Turkey | Ruhsatli | Ruhsatli | Regulator TITCK |
HEAD TO HEAD
18 registered trials include both
| NCT07732348 | Oral GnRH Antagonist (Linzagolix) Versus Injectable GnRH Antagonist in Controlled Ovarian Stimulation for In Vitro Fertilization: A Randomized Controlled Non-In NOT_YET_RECRUITING · updated 2026-09-30 |
|---|---|
| NCT04447872 | The LUTEAL Trial: Luteal Stimulation vs. Estrogen Priming Protocol UNKNOWN · updated 2023-10-16 |
| NCT04414761 | Live Birth Rate Between PPOS and GnRH Antagonist Protocol in Patients With Anticipated High Ovarian Response COMPLETED · updated 2023-08-30 |
| NCT04616729 | DEPO-Trigger Trial: GnRH Agonist DEPOt TRIGGER for Final Oocyte Maturation UNKNOWN · updated 2023-05-18 |
| NCT04108039 | Micronized Progesterone vs Gonadotropin-releasing Hormone (GnRH) Antagonist in Freeze-all IVF Cycles. COMPLETED · updated 2023-05-15 |
| NCT02912988 | Letrozole in Stimulated IVF Cycles COMPLETED · updated 2023-05-10 |
| NCT04071574 | Comparative Study on the Efficacy of Ovarian Stimulation Protocols on the Success Rate of ICSI in Female Infertility COMPLETED · updated 2023-05-09 |
| NCT04854707 | An Observational Study of Follitropin Alpha Biosimilar: the Real-world Data COMPLETED · updated 2021-10-22 |
| NCT04993924 | GnRH Antagonist Pre-treatment in the Early Follicular Phase for Resolution of a Baseline Functional Ovarian Cyst UNKNOWN · updated 2021-10-13 |
| NCT05071339 | GnRH Antagonist Pre-treatment for the Prevention of Asynchronous Follicular Growth UNKNOWN · updated 2021-10-08 |
| NCT03291821 | DuoStim in Cases of PGT: Comparison of Embryo Quantity and Embryonic Quality Using MitoScore COMPLETED · updated 2020-12-29 |
| NCT03477929 | Cetrorelix and Ganirelix Flexible Protocol for (IVF) UNKNOWN · updated 2018-03-27 |
| NCT01590173 | Addition of Prednisolone and Heparin in Patients Undergoing IVF With Failed IVF Cycles COMPLETED · updated 2016-07-19 |
| NCT01798862 | Endometrial Injury and IVF Outcome Parameters in Patients With Failed IVF Cycles COMPLETED · updated 2016-06-10 |
| NCT01669291 | Effect of GnRH Antagonist vs Agonist Long on IVF Outcome, Peak Estradiol Level,and Duration of Stimulation COMPLETED · updated 2014-06-04 |
| NCT00298025 | A Study to Compare the Safety and Efficacy of Cetrotide® 3 Milligram (mg) Versus Antagon™ in Women Undergoing Ovarian Stimulation COMPLETED · updated 2014-03-26 |
| NCT01888744 | Preimplantation Genetic Diagnosis (PGD) With Gonadotropin-releasing Hormone (GnRH) Agonist Versus Antagonist COMPLETED · updated 2013-06-28 |
| NCT01636505 | The Results of Preimplantation Genetic Diagnosis and Preimplantation Genetic Screening of Embryos Obtained From GnRH-agonist Long and GnRH-antagonist Ovarian St UNKNOWN · updated 2012-07-10 |
Values reproduce public registers on the dates shown. This comparison states no view on which compound is preferable, safer or more effective. Not medical, legal or regulatory advice.
WEEKLY
Register Watch, weekly
New trials, approvals and enforcement actions. One email a week.